Exome Asset Management LLC Buys Shares of 80,730 Zenas BioPharma, Inc. $ZBIO

Exome Asset Management LLC bought a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO) in the first quarter, Holdings Channel reports. The institutional investor bought 80,730 shares of the company’s stock, valued at approximately $1,578,000.

Several other institutional investors have also modified their holdings of ZBIO. Quarry LP boosted its position in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma during the third quarter worth about $30,000. GF Fund Management CO. LTD. purchased a new position in Zenas BioPharma during the fourth quarter worth about $38,000. BNP Paribas Financial Markets raised its stake in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the period. Finally, CWM LLC boosted its holdings in Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares during the last quarter.

Insider Activity at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were purchased at an average cost of $16.88 per share, for a total transaction of $1,012,800.00. Following the acquisition, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. The trade was a 162.48% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 22.00% of the company’s stock.

Zenas BioPharma Stock Up 8.0%

Shares of ZBIO opened at $32.82 on Tuesday. The company’s 50-day moving average price is $23.29 and its 200 day moving average price is $22.23. Zenas BioPharma, Inc. has a 12-month low of $13.50 and a 12-month high of $44.60. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04. The firm has a market cap of $2.07 billion, a P/E ratio of -3.87 and a beta of -0.96.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter in the previous year, the business posted ($0.80) EPS. On average, sell-side analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZBIO. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings lowered shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Morgan Stanley upped their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Finally, Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.29.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.